TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage company focused on RNA-based therapies for cancer, has announced the appointment of Anna Moore, PhD, as Chair of its Scientific Advisory Board and the execution of a sponsored research agreement with Michigan State University. These developments are expected to bolster the company's pipeline, particularly its lead candidate TTX-MC138, which targets metastatic tumors overexpressing microRNA-10b.
Dr. Moore, a prominent researcher in molecular imaging and nanomedicine, will provide strategic guidance on research and development efforts. Her expertise is expected to support TransCode's mission to develop first-in-class therapeutics for advanced cancers. The research agreement with Michigan State University aims to evaluate TTX-MC138 in combination with other therapies, potentially accelerating its path to clinical application.
TransCode's lead candidate, TTX-MC138, is designed to treat metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. The company also has a portfolio of other therapeutic candidates aimed at mobilizing the immune system to recognize and destroy cancer cells. This announcement underscores the growing interest in RNA-based therapeutics and their potential to address high-risk and advanced cancers.
For more details, the full press release is available at https://ibn.fm/NA2NH. Additional information about TransCode Therapeutics can be found on their website, and the latest news and updates relating to RNAZ are available in the company's newsroom at https://ibn.fm/RNAZ.
